Skip to main content

Patellofemoral Dislocation

0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CONMED
CONMEDCO - Greenwood Village
2 programs
MPFL repair with Biobrace augmentationN/A1 trial
Medial patellofemoral ligament reconstructionN/A1 trial
Active Trials
NCT06169800Recruiting20Est. Jun 2027
NCT05759039Recruiting32Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
CONMEDMPFL repair with Biobrace augmentation
CONMEDMedial patellofemoral ligament reconstruction

Clinical Trials (2)

Total enrollment: 52 patients across 2 trials

NCT06169800CONMEDMPFL repair with Biobrace augmentation

Biologic Augment of the Medial Patellofemoral Ligament Following Primary Lateral Patellofemoral Dislocation (BioPPD)

Start: Jan 2024Est. completion: Jun 202720 patients
N/ARecruiting
NCT05759039CONMEDMedial patellofemoral ligament reconstruction

SHould You TransFer the Tubercle?

Start: Sep 2023Est. completion: Sep 202632 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 52 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.